Have you accessed Homologous Recombination Deficiency (HRD) testing or have tried to access it?
Ovarian Cancer Canada (OCC) is gathering input from patients and caregivers to support a submission to Canada's Drug Agency (CDA) as part of its review of the value of HRD testing. We are seeking individuals who have accessed HRD testing, or have tried to access HRD testing, to participate in a confidential 45-minute telephone interview to share their lived experience.
To learn more or take part, please contact Alexandria Tadman at atadman@ovariancanada.org by May 29, 2026.
-------------------------------------------